TRACON Pharmaceuticals (TCON) Scheduled to Post Quarterly Earnings on Wednesday

TRACON Pharmaceuticals (NASDAQ:TCON) will be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). On average, analysts expect TRACON Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of TCON traded up $0.01 during mid-day trading on Monday, hitting $0.47. 30,176 shares of the company’s stock were exchanged, compared to its average volume of 129,443. TRACON Pharmaceuticals has a 52 week low of $0.42 and a 52 week high of $2.55. The stock has a 50-day moving average of $0.60. The stock has a market capitalization of $13.80 million, a price-to-earnings ratio of -0.36 and a beta of 2.46. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.44 and a current ratio of 2.44.

TCON has been the topic of several recent research reports. Zacks Investment Research cut shares of TRACON Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 18th. BTIG Research cut shares of TRACON Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, April 12th.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.

Further Reading: Golden Cross

Earnings History for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.